MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immunohistochemistry or IHC

Often used to diagnose cancer, Immunohistochemistry or IHC is a process by which antibodies are detected in tissue samples by use of a specific antigen or antigens. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue (also see “Serum Marker/Blood Test“).

GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung

American Journal of Surgical Pathology 2017 June [Epub ahead of print] [Link] Berg KB, Churg A Abstract The separation of sarcomatoid and desmoplastic malignant mesotheliomas from sarcomatoid carcinomas of the lung metastatic to the pleura may be difficult, since both types of tumor can be morphologically similar and are frequently positive only for pan-keratin. GATA […]

Comments Off on GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung

Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

Oncotarget 2017 May [Epub ahead of print] [Link] Lapa C, Kircher S, Schirbel A, Rosenwald A, Kropf S, Pelzer T, Walles T, Buck AK, Weber WA, Wester HJ, Herrmann K, Lückerath K Abstract C-X-C motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. This […]

Comments Off on Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma

International Journal of Oncology 2017 May [Epub ahead of print] [Link] Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer for which more effective treatments are needed. In this […]

Comments Off on DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma

A Subset of Malignant Mesotheliomas in Young Adults are Associated With Recurrent EWSR1/FUS-ATF1 Fusions

The American Journal of Surgical Pathology 2017 May 12 [Epub ahead of print] [Link] Desmeules P, Joubert P, Zhang L, Al-Ahmadie HA, Fletcher CD, Vakiani E, Delair DF, Rekhtman N, Ladanyi M, Travis WD, Antonescu CR Abstract Malignant mesothelioma (MM) is a rare, aggressive tumor often associated with asbestos exposure and characterized by complex genetic […]

Comments Off on A Subset of Malignant Mesotheliomas in Young Adults are Associated With Recurrent EWSR1/FUS-ATF1 Fusions

Multiple malignant epithelioid mesotheliomas of the liver and greater omentum: a case report and review of the literature

Surgical Case Reports [Epub May 10] [Link] Minami K, Okumura H, Hiwatashi K, Matsukita S, Setoyama T, Minamimagari K, Tsuruta Y, Kanetsuki I, Ogura Y, Maenohara S, Natsugoe S Abstract BACKGROUND: Malignant mesothelioma commonly arises from the pleura, but can also arise from the peritoneum, pericardium, and tunica vaginalis testis. However, malignant mesothelioma of the […]

Comments Off on Multiple malignant epithelioid mesotheliomas of the liver and greater omentum: a case report and review of the literature

BAP1 mutations in high-grade meningioma: implications for patient care

Neuro-oncology 2017 May [Epub ahead of print] [Link] Shankar GM, Santagata S Abstract We have recently shown that the BAP1 (BRCA1-associated protein-1) tumor suppressor gene is inactivated in a subset of clinically-aggressive meningiomas that display rhabdoid histomorphology. Immunohistochemistry for BAP1 protein provides a rapid and inexpensive method for screening suspected cases. Notably, some patients with […]

Comments Off on BAP1 mutations in high-grade meningioma: implications for patient care

Targeting YAP in malignant pleural mesothelioma

Journal of Cellular and Molecular Medicine 2017 Ma 4 [Epub ahead of print] [Link] Zhang WQ, Dai YY, Hsu PC, Wang H, Cheng L, Yang YL, Wang YC, Xu ZD, Liu S, Chan G, Hu B, Li H, Jablons DM, You L Abstract Malignant mesothelioma is an aggressive cancer that is resistant to current therapy. […]

Comments Off on Targeting YAP in malignant pleural mesothelioma

miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology

Cancer 2017 April 27 [Epub ahead of print] [Link] Cappellesso R, Galasso M, Nicolè L, Dabrilli P, Volinia S, Fassina A Abstract BACKGROUND: Malignant pleural mesothelioma is a rare tumor with a dismal prognosis, usually presenting with recurrent effusions. However, the majority of malignant pleural effusions are due to lung adenocarcinoma (AdC). The distinction between […]

Comments Off on miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology

Analysis of fibulin-3 after exposure to asbestos-like fibers.

Environmental Research 2017 April [Epub ahead of print] [Link] Rapisarda V, Caltabiano R, Musumeci G, Castrogiovanni P, Ferrante M, Ledda C, Lombardo C, Graziano AC, Cardile V, Loreto C Abstract A significantly increased incidence of malignant mesothelioma in Biancavilla (Sicily, Italy) has been ascribed to exposure to fluoro-edenite, a fibrous amphibole extracted from a local […]

Comments Off on Analysis of fibulin-3 after exposure to asbestos-like fibers.

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

The Lancelot: Oncology 2017 March [Epub ahead of print] [Link] Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E Abstract BACKGROUND: Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. We assessed the safety and efficacy of pembrolizumab […]

Comments Off on Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial